OakChart

SciSparc Ltd

SPRCHealthcare·Biotechnology·Israel·Nano·NASD·Nov 11 • 4:00 PM ET

0.3982+0.0192 (5.07%)
2026-11-11 23:39 CET
Market cap
0.78 USD m
Revenue, TTM
0.68 USD m
Net income, TTM
-8.22 USD m
Free cash flow, TTM
-5.84 USD m
EPS diluted, TTM
-79.46
P/E
-
Compare

Price

SPRC against its 20, 50 and 200-day averages
2050200
0.005.0010.0015.0020.0019.2M38.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SPRCclose 0.4020-day 0.9150-day 3.20200-day 5.250.40

98.7% under the 52-week high of 29.88 on 26 Nov 2025. 52-week low 0.37 on 10 Nov 2026. Last 15 sessions, 378.5% high to low

Volume 0.10× normal · the line is the 50-bar volume average

Profile

SPRC
52-week range, 0% of the way up
0.3729.88

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. It operates through the Drug Development and Online Sales segments. The Drug Development segment focuses on cannabinoid molecules to be approved by an official regulatory authority. The Online Sales segment consists of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

Employees3
IPOAug 30, 2021
Beta2.71
ATR, 14d0.27
Rel volume0.10
Short float3.43%
Insider own1.85%
Inst own2.62%

Snapshot

6 groups

Valuation

Index-
Market Cap0.82M
Enterprise Value6.37M
Income-8.22M
Sales0.68M
Book/sh6.79
Cash/sh2.17
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees3
IPOAug 30, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S1.21
P/B0.06
P/C0.18
P/FCF-
EV/EBITDA-
EV/Sales9.37
Quick Ratio0.86
Current Ratio0.87
Debt/Eq0.68
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-79.46
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y31.81% -13.87%
Sales past 3/5Y-14.03% -
EPS Y/Y TTM62.32%
Sales Y/Y TTM-26.75%
EPS Q/Q-
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own1.85%
Insider Trans-1.21%
Inst Own2.62%
Inst Trans3.49%
ROA-69.59%
ROE-519.89%
ROIC-208.42%
Gross Margin51.25%
Oper. Margin-660.53%
Profit Margin-1210.90%
SMA20-56.17%
SMA50-87.56%
SMA200-92.41%
Trades-

Technical

Shs Outstand2.06M
Shs Float2.02M
Short Float3.43%
Short Ratio0.05
Short Interest0.07M
52W High29.88 -98.67%
52W Low0.37 6.93%
Volatility14.97% 27.74%
ATR (14)0.27
RSI (14)15.85
Beta2.71
Rel Volume0.10
Avg Volume1.34M
Volume137,270

Performance

Perf Week-22.32%
Perf Month-89.89%
Perf Quarter-94.05%
Perf Half Y-92.07%
Perf YTD-96.75%
Perf Year-98.38%
Perf 3Y-99.95%
Perf 5Y-100.00%
Perf 10Y-
Recom-
Target Price-
Prev Close0.38
Price0.40
Change %5.07%

Peers

Mkt cap
TickerCompanyMkt cap
ARTLArtelo Biosciences Inc1.20M
SILOSILO Pharma Inc2.92M
SKYESkye Bioscience Inc4.06M
CMNDClearmind Medicine Inc2.51M
LEXXLexaria Bioscience Corp9.78M
IGCIGC Pharma Inc23.21M
ENVBEnveric Biosciences Inc6.67M
PPBTPurple Biotech Ltd ADR2.41M
SCNIScinai Immunotherapeutics Ltd ADR0.69M
QNTMQuantum BioPharma Ltd15.69M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
SMITH JAMES EDMOND10% OwnerJun 22 '26Proposed Sale7.9073,909583,881Jun 22 01:46 PM
Shrem ItschakDirectorJun 01 '26Sale10.004624,62010,596Jun 03 08:00 AM

News

latest 14 of 200
  • NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome (NewMediaWire) -10.45%
  • SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome (GlobeNewswire)
  • SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications (GlobeNewswire) -17.65%
  • SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies (GlobeNewswire) -44.90%
  • SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture (GlobeNewswire) +7.16%
  • SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations (GlobeNewswire) +9.63%
  • SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies (GlobeNewswire)
  • NeuroThera Labs Achieves Significant Enrollment Momentum in SCI210 Autism Clinical Trial (NewMediaWire) -14.48%
  • SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI-210 Autism Clinical Trial (GlobeNewswire)
  • Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
  • SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board (GlobeNewswire)
  • SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation (GlobeNewswire)
  • SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million (GlobeNewswire)
  • NeuroThera Labs Inc. Closes First Tranche of Non-Brokered Private Placement (NewMediaWire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-5,946--13,8830.00-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-245.7-262.801-137.297-461.13-13883.425-2784.076-2372.691-203.893-882.643
Period201720182019202020212022202320242025
EPS, quarterly
Period
Sales, annual000001.3472.8791.3060.856
Period201720182019202020212022202320242025
Sales, quarterly
Period
Shares, annual0.0280.0290.0470.0570.0010.0010.0040.0570.041
Period201720182019202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.680.861.312.881.350.000.000.000.00
Cost of Goods Sold Incl. D&A0.330.421.170.680.510.030.160.180.15
Gross Profit0.350.440.142.200.84-0.03-0.16-0.18-0.15
Selling, General and Administrative Excl. Other4.839.197.387.979.135.742.393.936.93
Research and Development2.732.101.711.642.801.990.651.642.71
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-4.49-8.75-7.24-5.77-8.29-5.77-2.55-4.11-7.08
Interest Expense8.310.010.030.010.040.010.030.570.12
Unusual Expense0.125.671.15-0.12-7.060.00-0.63-0.29-0.31
Net Income Before Taxes-9.02-12.06-7.06-5.65-2.47-5.79-3.54-4.48-6.53
Income Taxes0.000.00-0.010.020.010.000.000.000.00
Consolidated Net Income-9.20-12.56-7.47-5.88-2.59-5.79-3.54-4.48-6.53
Net Income From Continuing Operations-8.22-12.18-6.28-5.12-2.59-5.79-3.48-4.48-6.53
Net Income-8.22-12.18-6.28-5.12-2.59-5.79-3.48-4.79-8.52
EPS (Recurring)-14.01-0.60-177.71-2,410.63-8,093.76-13,883.43-519.51-143.14-269.47
EPS (Basic, Before Extraordinaries)-79.46-882.64-203.89-2,372.69-2,784.08-13,883.42-461.13-137.30-262.80
EPS (Diluted)-79.46-882.64-203.89-2,372.69-2,784.08-13,883.42-461.13-137.30-262.80
EBITDA-4.35-8.52-6.76-5.24-8.10-5.74-2.39-3.93-6.93
Non-Operating Income (Expense)3.902.361.370.01-1.21-0.01-1.59-0.090.36
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.196.520.440.080.690.040.090.550.60
Price To Earnings Ratio---2.51-----
Price To Sales Ratio4.72197.301.610.692.57----
Gross Margin51.2551.0510.7276.2862.21----
Operating Margin-660.53-1,022.08-554.52-200.52-615.22----
Net Margin-1,210.90-1,422.78-481.16-177.91-192.43----
Shares Outstanding0.580.040.060.000.000.000.060.050.03
Market Capitalization0.780.783.901.382.6619.262,064.96--

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S22023S12022S2
Total Revenue0.280.400.460.470.840.911.971.35
Cost of Goods Sold Incl. D&A0.160.170.290.430.37-1.270.49
Gross Profit0.120.230.170.030.47-0.700.86
Selling, General and Administrative Excl. Other5.01-0.189.323.754.004.033.674.33
Research and Development1.581.160.940.870.840.860.781.33
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.890.40-9.15-3.71-3.53-3.39-2.97-3.47
Interest Expense1.177.141.060.080.270.180.881.11
Unusual Expense0.000.120.001.340.001.040.00-7.83
Net Income Before Taxes-6.05-2.96-9.10-3.58-3.48-2.83-2.823.25
Income Taxes0.000.000.00-0.01-0.010.010.010.01
Consolidated Net Income-6.05-3.15-9.41-3.79-3.68-2.95-2.933.17
Net Income From Continuing Operations-5.37-2.85-9.33-2.84-3.44-2.24-2.883.17
Net Income-5.37-2.85-9.33-2.84-3.44-2.24-2.883.17
EPS (Recurring)-9.24-68.23-161.28-33.18-321.30-404.54-1,921.87-1,673.50
EPS (Basic, Before Extraordinaries)-9.24-70.21-161.28-49.60-321.30-599.62-1,921.872,288.99
EPS (Diluted)-9.24-70.21-161.28-49.60-321.30-599.62-1,921.872,288.99
EBITDA-4.800.45-8.96-3.45-3.31-3.12-2.70-3.31
Non-Operating Income (Expense)0.013.891.111.560.321.201.020.00
Stock Option Compensation Expense0.926.260.260.430.010.030.050.04
Price To Earnings Ratio-----2.517.35-
Price To Sales Ratio4.720.583.672.980.931.201.223.81
Gross Margin42.9657.2237.096.8756.43-35.7563.77
Operating Margin-1,720.77101.77-1,985.03-797.21-419.88-373.76-150.46-257.91
Net Margin-1,891.20-721.77-2,023.43-609.87-409.76-247.19-146.04235.12
Shares Outstanding0.580.040.060.060.020.000.000.00
Market Capitalization0.780.503.493.900.571.384.042.66

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments4.611.565.143.636.921.960.881.509.22
Short Term Receivables0.214.960.290.172.560.290.060.690.05
Inventories0.070.110.740.670.000.000.000.000.00
Other Current Assets0.540.870.280.040.350.310.010.250.22
Total Current Assets5.447.506.454.519.822.550.952.439.50
Net Property, Plant & Equipment0.020.060.110.060.090.010.172.110.05
Total Investments and Advances1.001.311.441.320.000.000.020.020.00
Intangible Assets1.171.483.194.720.000.000.000.000.00
Other Assets0.000.000.000.000.000.000.000.000.02
Total Assets7.6210.3511.1810.619.922.561.154.569.57
Short Term Debt Incl. Current Port. of LT Debt0.370.040.050.030.040.190.071.150.00
Accounts Payable0.290.210.801.201.200.280.340.980.40
Other Current Liabilities1.601.150.722.930.510.670.642.360.78
Total Current Liabilities2.251.401.574.161.761.131.054.481.18
Long Term Debt0.000.010.020.000.020.000.090.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Other Liabilities0.220.000.000.000.000.000.000.000.00
Total Liabilities2.481.411.594.161.771.131.144.481.18
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity4.248.157.616.458.141.430.010.188.39
Total Shareholders Equity4.248.157.616.458.141.430.010.188.39
Accumulated Minority Interest0.910.791.970.000.000.000.00-0.110.00
Total Equity5.158.949.596.458.141.430.010.088.39
Total Liabilities & Stockholders Equity7.6210.3511.1810.619.922.561.154.569.57
Book Value Per Share104.40142.322,036.344,661.1512,939.2725.200.306.48294.69
Tangible Book Value Per Share75.58116.511,183.451,251.8412,939.2725.200.306.48294.69
Full-Time Employees32434118118
Price to Book Ratio0.060.480.340.882.37272.14---
Return on Assets-135.56-58.38-47.02-25.26-92.79-187.46-156.77-92.51-115.52
Return on Equity-196.55-79.71-72.84-35.53-120.97-482.27-4,501.51-152.41-139.35
Return on Invested Capital-287.31-76.98-67.06-40.19-70.95-243.50-4,438.89-4,607.03-74.43
Quick Ratio2.385.283.630.925.592.250.910.548.07
Current Ratio2.415.364.101.095.592.250.910.548.07

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-9.20-12.56-7.47-5.88-2.59-5.79-3.54-4.69-8.95
Depreciation0.140.230.480.540.190.030.160.180.15
Other Funds (Non Cash)2.576.751.750.29-4.810.050.411.930.28
Funds from Operations-6.50-5.58-5.24-5.05-7.21-5.70-2.96-2.58-8.53
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.661.450.14-0.83-0.700.64-1.35-2.121.40
Cash from Operating Activities-5.84-4.14-5.10-5.89-7.92-5.06-4.31-4.70-7.13
Capital Expenditures0.000.000.000.00-4.87-0.040.00-0.00-0.02
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.012.990.000.000.000.720.06
Purchase or Sale of Investments0.700.602.40-4.09-2.200.000.02-0.00-0.01
Purchase of Investments0.00-0.10-0.60-4.09-2.200.000.00-0.00-0.01
Sale Or Maturity of Investments0.700.703.000.000.000.000.02-0.00
Other Uses0.00-2.00-4.080.000.000.000.000.00-2.13
Other Sources0.120.000.000.000.000.000.000.550.00
Cash from Investing Activities0.82-1.40-1.67-1.10-7.07-0.040.021.27-2.09
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock8.977.376.265.5511.7810.275.142.870.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock8.977.376.265.5511.7810.275.142.870.00
Proceedsfrom Stock Options7.856.256.265.559.017.702.772.190.00
Issuance or Reduction of Debt, Net2.240.550.000.000.00-0.190.250.001.57
Change in Long Term Debt-0.000.000.000.000.000.000.001.48
Issuance of Long Term Debt-0.000.000.000.000.000.000.001.48
Reduction of Long Term Debt-0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.710.710.000.000.000.000.000.00-0.04
Other Financing Activities Uses0.000.000.000.000.000.000.000.00-0.04
Cash from Financing Activities7.918.596.195.5011.7010.065.362.801.54
Exchange Rate Effect-----0.000.000.01-0.02
Net Change in Cash2.893.05-0.58-1.49-3.294.961.08-0.62-7.71
Free Cash Flow-5.84-4.14-5.10-5.89-7.92-5.10-4.31-4.70-7.15
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Cash & Short Term Investments4.464.611.571.562.625.14
Short Term Receivables0.580.211.034.960.320.29
Inventories0.070.070.150.110.410.74
Other Current Assets0.450.54-0.87-0.28
Total Current Assets5.565.442.757.503.366.45
Net Property, Plant & Equipment0.010.020.040.060.070.11
Total Investments and Advances0.491.000.971.311.601.44
Intangible Assets12.431.171.381.483.013.19
Other Assets0.000.000.000.000.000.00
Total Assets18.497.625.1410.3510.4811.18
Short Term Debt Incl. Current Port. of LT Debt2.680.372.450.040.040.05
Accounts Payable0.840.780.810.821.160.80
Other Current Liabilities2.841.101.780.550.600.72
Total Current Liabilities6.372.255.041.401.801.57
Long Term Debt0.000.000.000.010.030.02
Other Liabilities0.850.220.180.000.000.00
Total Liabilities7.222.485.221.411.831.59
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity3.944.24-0.788.156.927.61
Total Shareholders Equity3.944.24-0.788.156.927.61
Accumulated Minority Interest7.330.910.700.791.741.97
Total Equity11.275.15-0.088.948.669.59
Total Liabilities & Stockholders Equity18.497.625.1410.3510.4811.18
Book Value Per Share6.79104.40-13.16142.32364.712,036.34
Tangible Book Value Per Share-14.6175.58-36.45116.51206.281,183.45
Price to Book Ratio0.060.12-4.460.480.070.34
Return on Assets-69.59-135.56-155.82-58.38-55.80-47.02
Return on Equity-519.89-196.55-396.55-79.71-103.20-72.84
Return on Invested Capital-136.15-67.26--34.82-49.55-29.35
Quick Ratio0.862.380.525.281.633.63
Current Ratio0.872.410.555.361.864.10

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Net Income-6.05-3.15-9.41-3.79-3.68-2.95
Depreciation0.090.040.190.260.220.27
Other Funds (Non Cash)2.340.236.521.490.260.23
Funds from Operations-3.62-2.88-2.70-2.04-3.20-2.45
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.060.600.84-0.871.00-0.20
Cash from Operating Activities-3.56-2.28-1.86-2.91-2.20-2.65
Capital Expenditures0.000.000.000.00-0.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.010.002.99
Purchase or Sale of Investments0.000.70-0.102.310.09-3.00
Purchase of Investments0.000.00-0.10-0.00-0.60-3.00
Sale Or Maturity of Investments0.000.700.002.310.690.00
Other Uses0.000.00-2.00-4.080.000.00
Other Sources0.120.000.000.000.000.00
Cash from Investing Activities0.120.70-2.10-1.760.09-0.02
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.607.370.003.532.722.72
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.607.370.003.532.722.72
Proceedsfrom Stock Options1.606.250.003.532.722.72
Issuance or Reduction of Debt, Net1.69-3.443.990.000.000.00
Change in Long Term Debt0.00--0.000.000.00
Issuance of Long Term Debt0.00--0.000.000.00
Reduction of Long Term Debt0.00--0.000.000.00
Net Financing Active Other Cash Flow0.000.710.002.40-2.400.00
Other Financing Activities Uses0.000.000.002.40-2.400.00
Cash from Financing Activities3.294.623.975.910.282.69
Net Change in Cash-0.153.050.011.24-1.830.02
Free Cash Flow-3.56-2.28-1.86-2.91-2.20-2.65

Revenue breakdown

Pharmaceutical Preparations2024: 1.31M 2025: 856.00K
Israel2024: 1.31M 2025: 856.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.43%0.1M2.0M1.33M
2026-10-152.17%0.0M0.6M708.78K
2026-09-302.03%0.0M0.6M181.74K
2026-09-151.96%0.0M0.6M186.98K
2026-08-312.76%0.0M0.6M335.20K
2026-08-143.07%0.0M0.6M912.82K
2026-07-316.78%0.0M0.6M901.53K
2026-07-151.80%0.0M0.6M1.09M
2026-06-304.65%0.0M0.6M1.07M
2026-06-153.44%0.0M0.6M1.05M
2026-05-2967.54%0.4M0.6M986.16K
2026-05-151.26%0.0M0.6M406.67K
2026-04-305.97%0.0M0.5M411.36K
2026-04-155.92%0.0M0.5M98.60K
2026-03-317.93%0.0M0.4M175.18K
2026-03-1321.10%0.1M0.4M187.28K
2026-02-274.77%0.0M0.3M139.98K
2026-02-134.53%0.0M0.3M230.65K
2026-01-305.59%0.0M0.4M228.13K
2026-01-1512.76%0.0M0.4M220.30K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-11-096-K/A2026-11-03SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-26SEC
2026-10-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-23SEC
2026-10-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-15SEC
2026-10-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-15SEC
2026-10-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-07SEC
2026-09-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-09-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-02SEC
2026-08-31EFFECTEffectiveness filing by commission orderSEC
2026-08-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-26SEC
2026-08-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-24SEC
2026-08-19F-3/ASEC
2026-08-1920-F/A2025-12-31SEC
2026-08-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-18SEC
2026-08-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-12SEC
2026-08-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-05SEC
2026-07-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-31SEC
2026-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-29SEC
2026-07-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-15SEC
2026-07-133/A2026-03-18SEC
2026-07-133/A2026-03-18SEC
2026-07-133/A2026-03-18SEC
2026-07-133/A2026-03-18SEC
2026-07-133/A2026-03-18SEC
2026-07-133/A2026-03-18SEC
2026-07-133/A2026-03-18SEC
2026-07-133/A2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-06004.62K1
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HRT FINANCIAL LP3.70%
JANE STREET GROUP, LLC2.88%
CITADEL ADVISORS LLC1.93%
UBS Group AG0.30%
JPMORGAN CHASE & CO0.04%
MORGAN STANLEY0.03%
SBI Securities Co., Ltd.0.02%
ROYAL BANK OF CANADA0.01%

Funds

Fund% owned
First Trust Emerging Markets Small Cap AlphaDEX Fund656.54%
JNL Multi-Manager International Small Cap Fund307.26%
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND148.68%
iShares Core MSCI EAFE ETF109.96%
VANGUARD DEVELOPED MARKETS INDEX FUND89.87%
iShares MSCI EAFE Small-Cap ETF36.76%
VANGUARD GLOBAL EX-U.S. REAL ESTATE INDEX FUND34.92%
Schwab International Equity ETF26.67%
iShares Core MSCI Total International Stock ETF26.09%
iShares Core MSCI International Developed Markets ETF23.86%

OakChart. SPRC. Cached 15 minutes.

Some panels did not load: ratings.